Zhongheng Group: The company has no direct research investment in Chinese patent medicine for new coronary pneumonia for the time being

Post date May 17, 2022 — 09:21 Post Lock

Key Data Concepts:
? These are the company names, stock quotes, topics, and entities related to this data.

Full Data

?
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets

Need this critical market data?

Access thousands of market events, data points, and news articles!

Already have an account?
Login

Related Data

【Company Frontline】Meikang Biotech adds the concept of "fangcang cabin hospital"

May 20, 2022 — 17:59

“14th Five-Year Plan” 11 major transportation project packages announced

May 20, 2022 — 17:59

Beingmate: The company is also actively sorting out and adjusting the large supermarket channels such as China Resources, Kidswant, and Wal-Mart

May 20, 2022 — 17:58

Asia Potash International: There is no exchange gain or loss problem

May 20, 2022 — 17:57

Kangtai Medical: The company's decline in sales of blood oxygen products in 2021 is mainly affected by changes in demand and the high base of the previous year

May 20, 2022 — 17:56

Unnamed Medicine: The company does not hold shares in Kexing Zhongwei

May 20, 2022 — 17:56

Huichuangda: In 2021, the company will strengthen the research and development of automated production lines, further improve the degree of automation of production lines, enhance production efficiency, and realize automated production of various processes

May 20, 2022 — 17:55

TANSUN: The company's business is stable, the orders on hand are sufficient, and the number of employees has maintained an increasing trend compared with the beginning of the year

May 20, 2022 — 17:55

Kangtai Medical: The company's new crown antigen detection kit is currently in the stage of product clinical performance evaluation in China, and has not yet been listed for sale in the domestic market

May 20, 2022 — 17:55

Home » News » Zhongheng Group: The company has no direct research investment in Chinese patent medicine for new coronary pneumonia for the time being